DK1691828T3 - Behandling af spastisk blære med botulinustoksin - Google Patents

Behandling af spastisk blære med botulinustoksin

Info

Publication number
DK1691828T3
DK1691828T3 DK04798493.5T DK04798493T DK1691828T3 DK 1691828 T3 DK1691828 T3 DK 1691828T3 DK 04798493 T DK04798493 T DK 04798493T DK 1691828 T3 DK1691828 T3 DK 1691828T3
Authority
DK
Denmark
Prior art keywords
bladder
unstable
sphincter
botulinum toxin
detrusor
Prior art date
Application number
DK04798493.5T
Other languages
English (en)
Inventor
Chris Dott
John Batchelor
D Arbigny Pierre Bernard
Roland Cherif-Cheikh
Original Assignee
Ipsen Pharma
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29764527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1691828(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Pharma, Ipsen Biopharm Ltd filed Critical Ipsen Pharma
Application granted granted Critical
Publication of DK1691828T3 publication Critical patent/DK1691828T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
DK04798493.5T 2003-12-04 2004-11-12 Behandling af spastisk blære med botulinustoksin DK1691828T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0328060.9A GB0328060D0 (en) 2003-12-04 2003-12-04 Botulinum toxin treatment
PCT/GB2004/004770 WO2005053733A1 (en) 2003-12-04 2004-11-12 Botulinum toxin treatment of spastic bladder

Publications (1)

Publication Number Publication Date
DK1691828T3 true DK1691828T3 (da) 2010-11-01

Family

ID=29764527

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04798493.5T DK1691828T3 (da) 2003-12-04 2004-11-12 Behandling af spastisk blære med botulinustoksin

Country Status (13)

Country Link
US (2) US20070275110A1 (da)
EP (1) EP1691828B1 (da)
JP (1) JP5107578B2 (da)
AT (1) ATE475429T1 (da)
CA (1) CA2547618C (da)
DE (1) DE602004028403D1 (da)
DK (1) DK1691828T3 (da)
ES (1) ES2347151T3 (da)
GB (1) GB0328060D0 (da)
PL (1) PL1691828T3 (da)
PT (1) PT1691828E (da)
RU (1) RU2350348C2 (da)
WO (1) WO2005053733A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
ES2509872T3 (es) 2005-03-03 2014-10-20 Allergan, Inc. Procedimientos para obtener una toxina clostrídica
US20090304747A1 (en) * 2006-05-16 2009-12-10 Mayo Foundation For Medical Education And Research Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
CA2678038C (en) 2007-02-15 2016-10-11 Allergan, Inc. Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis
MX2010004502A (es) 2007-10-23 2010-06-17 Allergan Inc Metodos para tratar trastornos neurologicos urogenitales usando toxinas clostridiales modificadas.
US10471150B2 (en) 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
WO2011089604A2 (en) 2010-01-20 2011-07-28 Theracoat Ltd Material and method for treating internal cavities
US20130171122A1 (en) * 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
RU2635466C2 (ru) * 2012-04-08 2017-11-13 Теракоат Лтд Препараты термообратимого гидрогеля для применения при лечении нарушений уротелия
JP2017532301A (ja) * 2014-09-24 2017-11-02 ウェルズリー ファーマスーティカルズ、エルエルシー 膀胱痙攣を低減するための医薬製剤およびその使用の方法
RU2605624C1 (ru) * 2015-11-23 2016-12-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) Способ лечения детрузорной гиперактивности
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
TWI810228B (zh) 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
CA3201129A1 (en) 2020-12-11 2022-06-16 Yulia HIONIDI Material and method for treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236956A (en) * 1988-11-04 1993-08-17 Kabi Pharmacia Aktiebolag Compounds for the treatment of urinary incontinence
SE8804003D0 (sv) * 1988-11-04 1988-11-04 Pharmacia Ab Compounds for the treatment of urinary incontinence
JPH0564661A (ja) * 1991-09-09 1993-03-19 Olympus Optical Co Ltd 体腔内挿入具
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5749845A (en) 1995-01-25 1998-05-12 Iotek, Inc. Delivering an agent to an organ
KR100544060B1 (ko) * 1997-07-15 2006-01-23 더 리젠트스 오브 더 유니버시티 오브 콜로라도 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도
US6630570B1 (en) * 1999-04-09 2003-10-07 Insitut für Diagnostikforschung GmbH Short-chain peptide-dye conjugates as contrast media for optical diagnosis
DE19917713A1 (de) * 1999-04-09 2000-10-19 Diagnostikforschung Inst Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik
US6579847B1 (en) * 2000-05-01 2003-06-17 Imarx Therapeutics Inc. Method and apparatus for vascular neuromuscular blockade
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6638246B1 (en) * 2000-11-28 2003-10-28 Scimed Life Systems, Inc. Medical device for delivery of a biologically active material to a lumen
US20020099356A1 (en) * 2001-01-19 2002-07-25 Unger Evan C. Transmembrane transport apparatus and method
DK1411978T3 (da) * 2001-07-27 2009-01-05 Univ Louisiana State Botulinum-toksin ved behandlingen eller forebyggelsen af acne
AU2002323151A1 (en) * 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
US20040067235A1 (en) * 2002-07-29 2004-04-08 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders

Also Published As

Publication number Publication date
EP1691828B1 (en) 2010-07-28
JP2007513127A (ja) 2007-05-24
WO2005053733A1 (en) 2005-06-16
US20070275110A1 (en) 2007-11-29
RU2350348C2 (ru) 2009-03-27
CA2547618C (en) 2014-05-27
DE602004028403D1 (de) 2010-09-09
PL1691828T3 (pl) 2011-01-31
JP5107578B2 (ja) 2012-12-26
EP1691828A1 (en) 2006-08-23
ATE475429T1 (de) 2010-08-15
ES2347151T3 (es) 2010-10-26
RU2006123561A (ru) 2008-01-10
US20090028907A1 (en) 2009-01-29
GB0328060D0 (en) 2004-01-07
CA2547618A1 (en) 2005-06-16
PT1691828E (pt) 2010-10-04
US8277822B2 (en) 2012-10-02

Similar Documents

Publication Publication Date Title
DK1691828T3 (da) Behandling af spastisk blære med botulinustoksin
Bustinduy et al. An update on female and male genital schistosomiasis and a call to integrate efforts to escalate diagnosis, treatment and awareness in endemic and non-endemic settings: the time is now
DK1475099T3 (da) Anvendelse af botulinum-toksin til behandling af urin-inkontinens
Smith et al. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra
Yang et al. Endogenous Klebsiella endophthalmitis associated with pyogenic liver abscess
Moulin Pain in central and peripheral demyelinating disorders: Multiple sclerosis and Guillain-Barre syndrome
US8871763B2 (en) Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies
RU2014103542A (ru) Способы лечения недержания, связанного с половой активностью
JP2007513127A5 (da)
Vera et al. MK-801, a non-competitive NMDA receptor antagonist, produces facilitation of the micturition reflex in awake, freely-moving rats
Schapiro The symptomatic management of multiple sclerosis
Rösche Treatment of spasticity
Angelico et al. Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions
Chao et al. Duloxetine treatment of long-term ketamine abuse-related lower urinary tract symptoms: a case report
Kroll The current role of Botox in a pediatric neurogenic bladder condition
US20220079996A1 (en) Pharmaceutical composition comprising amniotic fluid stem cell spheroid and the use thereof in treatment of urinary incontinence
RU2019132999A (ru) Способ лечения нейрогенной дисфункции мочевого пузыря, проявляющейся функциональной инфравезикальной обструкцией у женщин
Kuo EFFECTIVENESS OF PERIURETHRAL BOTULINUM TOXIN INJECTION IN THE TREATMENT OF VOIDING DYSFUNCTION DUE TO DETRUSOR UNDERACTIVITY AND NON-RELAXING URETHRAL SPHINCTER
Hatch Intraprostatic injection of penicillin
UA72418A (en) Method for treating hyperactivity of urinary bladder
Tiebin et al. Effectiveness of electrical stimulation of pelvic floor muscles in the treatment of urinary incontinence in patients with incomplete spinal cord injury
CN114042076A (zh) 一种肛门术后镇痛技术
Dzigowski et al. Efficacy and safety of botulinum toxin non-neurogenic administration, a single center, single surgeon 7 years experience Article published in Urologia Polska 2008/61/Supl. 1.
Al-shaham et al. Anal Fissure: Is it becoming a medical disorder? Review Article
Dougherty et al. Clinical Observations on the Nature of Urogenital Gonorrhea